Loading...

Merrimack Pharmaceuticals

BST:MP6N
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MP6N
BST
$80M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
MP6N Share Price and Events
7 Day Returns
4.9%
BST:MP6N
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-23.5%
BST:MP6N
-10.2%
DE Biotechs
-6%
DE Market
MP6N Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Merrimack Pharmaceuticals (MP6N) 4.9% -8.8% 21.7% -23.5% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • MP6N underperformed the Biotechs industry which returned -10.2% over the past year.
  • MP6N underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
MP6N
Industry
5yr Volatility vs Market
Related Companies

MP6N Value

 Is Merrimack Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Merrimack Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €5.292.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Merrimack Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Merrimack Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:MP6N PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.55
NasdaqGM:MACK Share Price ** NasdaqGM (2019-04-18) in USD $6
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Merrimack Pharmaceuticals.

BST:MP6N PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MACK Share Price ÷ EPS (both in USD)

= 6 ÷ -4.55

-1.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merrimack Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Merrimack Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Merrimack Pharmaceuticals's expected growth come at a high price?
Raw Data
BST:MP6N PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Merrimack Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Merrimack Pharmaceuticals's assets?
Raw Data
BST:MP6N PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.41
NasdaqGM:MACK Share Price * NasdaqGM (2019-04-18) in USD $6
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:MP6N PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MACK Share Price ÷ Book Value per Share (both in USD)

= 6 ÷ 4.41

1.36x

* Primary Listing of Merrimack Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merrimack Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Merrimack Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Merrimack Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MP6N Future Performance

 How is Merrimack Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Merrimack Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Merrimack Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Merrimack Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Merrimack Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:MP6N Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:MP6N Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:MP6N Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:MP6N Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -66 -61
2018-09-30 -92 -60
2018-06-30 -104 -53
2018-03-31 -153 -64
2017-12-31 -126 -75
2017-09-30 -132 -102
2017-06-30 -141 -123
2017-03-31 -127 -146
2016-12-31 -170 -155
2016-09-30 21 -143 -163
2016-06-30 38 -150 -179
2016-03-31 74 -124 -151

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Merrimack Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Merrimack Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:MP6N Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Merrimack Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:MP6N Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:MP6N Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.55
2018-09-30 -4.48
2018-06-30 -3.96
2018-03-31 -4.80
2017-12-31 -5.66
2017-09-30 -7.76
2017-06-30 -9.44
2017-03-31 -11.30
2016-12-31 -12.33
2016-09-30 -13.42
2016-06-30 -15.26
2016-03-31 -13.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Merrimack Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Merrimack Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Merrimack Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Merrimack Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Merrimack Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Merrimack Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MP6N Past Performance

  How has Merrimack Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Merrimack Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Merrimack Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Merrimack Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Merrimack Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Merrimack Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Merrimack Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:MP6N Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -60.77 15.30
2018-09-30 -59.72 16.21
2018-06-30 -52.73 15.80
2018-03-31 -63.89 27.09
2017-12-31 -74.84 28.45
2017-09-30 -101.93 34.81
2017-06-30 -123.21 37.89
2017-03-31 -145.72 31.23
2016-12-31 -154.51 32.05
2016-09-30 21.42 -163.42 40.37
2016-06-30 37.86 -179.37 50.88
2016-03-31 74.42 -150.73 55.06
2015-12-31 -151.79 24.05
2015-09-30 101.74 -109.83 46.74
2015-06-30 113.31 -95.14 37.88
2015-03-31 104.56 -90.47 33.48
2014-12-31 102.76 -83.29 30.52
2014-09-30 76.67 -106.65 28.25
2014-06-30 55.53 -118.38 25.31
2014-03-31 46.17 -130.36 22.48
2013-12-31 47.79 -130.93 21.19
2013-09-30 54.15 -122.63 19.33
2013-06-30 58.62 -106.20 18.49
2013-03-31 52.23 -96.21 17.01
2012-12-31 48.92 -93.38 15.81
2012-09-30 47.31 -88.79 14.87
2012-06-30 44.57 -86.26 13.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Merrimack Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Merrimack Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Merrimack Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Merrimack Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Merrimack Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MP6N Health

 How is Merrimack Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Merrimack Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Merrimack Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Merrimack Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Merrimack Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Merrimack Pharmaceuticals Company Filings, last reported 3 months ago.

BST:MP6N Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 58.82 14.87 71.28
2018-09-30 67.04 14.75 84.85
2018-06-30 62.28 0.00 60.00
2018-03-31 79.25 0.00 76.27
2017-12-31 96.28 0.00 93.44
2017-09-30 111.63 49.88 107.25
2017-06-30 104.48 48.91 135.50
2017-03-31 -277.14 218.04 17.16
2016-12-31 -252.66 216.86 21.52
2016-09-30 -227.14 216.87 48.47
2016-06-30 -201.56 215.54 82.67
2016-03-31 -217.14 259.84 132.39
2015-12-31 -183.69 257.66 185.61
2015-09-30 -140.67 126.26 62.35
2015-06-30 -143.06 124.18 67.66
2015-03-31 -128.82 122.08 91.77
2014-12-31 -102.07 120.00 124.03
2014-09-30 -99.86 118.66 153.68
2014-06-30 -77.13 116.19 92.75
2014-03-31 -65.80 113.81 124.18
2013-12-31 -43.13 111.68 155.20
2013-09-30 -16.64 111.33 182.49
2013-06-30 -58.34 40.56 62.14
2013-03-31 -32.14 40.33 86.69
2012-12-31 -6.42 39.86 109.95
2012-09-30 13.02 0.00 86.67
2012-06-30 33.09 0.00 106.71
  • Merrimack Pharmaceuticals's level of debt (25.3%) compared to net worth is satisfactory (less than 40%).
  • Merrimack Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Merrimack Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • Merrimack Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -14.2% each year.
X
Financial health checks
We assess Merrimack Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Merrimack Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MP6N Dividends

 What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Merrimack Pharmaceuticals dividends.
If you bought €2,000 of Merrimack Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Merrimack Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Merrimack Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:MP6N Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:MP6N Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Merrimack Pharmaceuticals has not reported any payouts.
  • Unable to verify if Merrimack Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Merrimack Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Merrimack Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Merrimack Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Merrimack Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Merrimack Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MP6N Management

 What is the CEO of Merrimack Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Peters
COMPENSATION $3,778,224
AGE 55
TENURE AS CEO 2.2 years
CEO Bio

Dr. Richard Peters, M.D., Ph.D. has been the Chief Executive Officer and President of Merrimack Pharmaceuticals, Inc. since February 6, 2017 and served as its Principal Financial Officer from June 2017 to August 21, 2017. Dr. Peters is a Harvard-trained physician-scientist. He has over 20 years of biotech (oncology and specialty care) experience including roles of increasing responsibility in medical affairs at Onyx Pharmaceuticals, Inc. and Amgen Inc. He served as Global Head of Rare Diseases and Senior Vice President at Genzyme Corporation (Sanofi Genzyme) from January 2015 to February 6, 2017 and served as its Vice President. He was responsible for a global, $3 billion per year business with 10 commercialized products and a robust, multi-product development pipeline focusing on several therapeutic areas. He joined Genzyme in 2008. He oversaw a portfolio of products that serves patients in more than 90 countries worldwide. He was a co-founder of Mednav, Inc. and served as its Chief Executive Officer. Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008, including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015, Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014, Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014 and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. He served as Deputy Head for the Genzyme Global Rare Diseases Division at Genzyme Therapeutic Products Limited Partnership. He served as Senior Director of Medical Affairs at Onyx Pharmaceuticals. He served as Director of Medical Affairs at Amgen Inc. He has been a Director of Merrimack Pharmaceuticals, Inc. since February 6, 2017. He serves as Scientific and Clinical Advisor at Aura Biosciences, Inc. He served as a Director of X4 Pharmaceuticals Inc. Dr. Peters has served on the faculty/clinical staff at Harvard Medical School/Massachusetts General Hospital in Boston. He began his medical training at the Université Catholique de Louvain in Brussels, Belgium. He has served as a consulting editor for JAMA and as a contributing editor for Science and has authored over 120 research articles and editorials. Dr. Peters earned his M.D. and Ph.D. in Pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston. He completed postgraduate training at Massachusetts General Hospital and a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School.

CEO Compensation
  • Insufficient data for Richard to compare compensation growth.
  • Richard's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Merrimack Pharmaceuticals management team in years:

2.1
Average Tenure
54
Average Age
  • The tenure for the Merrimack Pharmaceuticals management team is about average.
Management Team

Richard Peters

TITLE
President
COMPENSATION
$4M
AGE
55
TENURE
2.2 yrs

Jean Franchi

TITLE
CFO & Treasurer
COMPENSATION
$641K
AGE
52
TENURE
1.7 yrs

Jeffrey Munsie

TITLE
General Counsel
COMPENSATION
$1M
AGE
41
TENURE
2.1 yrs

Daryl Drummond

TITLE
Head of Research
COMPENSATION
$817K
AGE
49
TENURE
2.1 yrs

Tony Sinskey

TITLE
Co-Founder and Scientific Advisor
COMPENSATION
$4K
AGE
78

Geoffrey Grande

TITLE
Senior Director of Communications

Ellen Forest

TITLE
Head of Human Resources
AGE
54
TENURE
1.9 yrs

Fazal Khan

TITLE
Senior Vice President of Manufacturing
COMPENSATION
$691K
AGE
68
TENURE
13 yrs
Board of Directors Tenure

Average tenure and age of the Merrimack Pharmaceuticals board of directors in years:

4
Average Tenure
59
Average Age
  • The tenure for the Merrimack Pharmaceuticals board of directors is about average.
Board of Directors

Gary Crocker

TITLE
Chairman of the Board
COMPENSATION
$175K
AGE
66
TENURE
14.3 yrs

Richard Peters

TITLE
President
COMPENSATION
$4M
AGE
55
TENURE
2.2 yrs

Peter Sorger

TITLE
Chairman of Scientific Advisory Board
AGE
57

Jim Quigley

TITLE
Director
COMPENSATION
$126K
AGE
66
TENURE
6.8 yrs

John Dineen

TITLE
Director
COMPENSATION
$119K
AGE
55
TENURE
3.8 yrs

Ulrik Nielsen

TITLE
Co-Founder & Director
COMPENSATION
$104K
AGE
46
TENURE
4.3 yrs

Douglas Lauffenburger

TITLE
Member of Scientific Advisory Board

Russ Ray

TITLE
Director
COMPENSATION
$116K
AGE
71
TENURE
4.3 yrs

George Demetri

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$33K
AGE
61
TENURE
1.2 yrs

Peter Blume-Jensen

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Apr 19 Buy 22NW, LP Company 15. Apr 19 17. Apr 19 66,760 €5.31 €346,282
17. Apr 19 Buy 22NW, LP Company 15. Apr 19 17. Apr 19 66,760 €5.31 €346,282
09. Apr 19 Buy JFL Capital Management LP Company 05. Apr 19 08. Apr 19 37,278 €5.29 €194,849
09. Apr 19 Buy 22NW, LP Company 05. Apr 19 08. Apr 19 82,873 €5.43 €441,204
14. Mar 19 Buy 22NW, LP Company 22. Jan 19 11. Mar 19 252,916 €5.56 €1,304,131
14. Mar 19 Sell JFL Capital Management LP Company 14. Feb 19 15. Feb 19 -5,981 €5.34 €-31,547
19. Dec 18 Sell JFL Capital Management LP Company 07. Nov 18 07. Nov 18 -815 €4.20 €-3,425
19. Dec 18 Buy JFL Capital Management LP Company 05. Nov 18 19. Dec 18 188,841 €4.12 €239,549
02. Nov 18 Buy JFL Capital Management LP Company 08. Oct 18 31. Oct 18 941,502 €4.40 €4,142,449
X
Management checks
We assess Merrimack Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Merrimack Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MP6N News

Simply Wall St News

MP6N Company Info

Description

Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Details
Name: Merrimack Pharmaceuticals, Inc.
MP6N
Exchange: BST
Founded: 1993
$71,186,421
13,342,784
Website: http://www.merrimack.com
Address: Merrimack Pharmaceuticals, Inc.
One Kendall Square,
Suite B7201,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MACK Common Stock Nasdaq Global Market US USD 29. Mar 2012
DB A1JHBG Common Stock Deutsche Boerse AG DE EUR 29. Mar 2012
BST MP6N Common Stock Boerse-Stuttgart DE EUR 29. Mar 2012
Number of employees
Current staff
Staff numbers
27
Merrimack Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:43
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2018/03/12
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.